Clinical research of the effect and the safety with 0.1% bromfenac sodium hydrate ophthalmic solution and 0.1% betamethasone sodium phosphate ophthalmic, otic and nasal solution in patients with diabetic macular edema

INTERVENTION: 0.1% bromfenac sodium hydrate ophthalmic solution 0.1% betamethasone sodium phosphate ophthalmic , otic and nasal solution CONDITION: Diabetic macular edema PRIMARY OUTCOME: The change value of the central macular thickness at 12 weeks after starting administration of test drug from that at the day of starting administration INCLUSION CRITERIA: On screening 1)Patients with DME 2)Patients with HbA1c value less than 10% 3)Patients with visual acuity more than 0.5 On starting administration 4)Patients with 250‐500 of central macular thickness